Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial

2020/07/20 by Feng-Cai Zhu, Fengcai Zhu, Xu-Hua Guan +32 · 3 citations
Biochemistry, Genetics and Molecular Biology · Medicine · #COVID-19 Clinical Research Studies #SARS-CoV-2 and COVID-19 Research #Virus-based gene therapy research

paper · pdf · doi:10.1016/s0140-6736(20)31605-6

openalex publication_date 2020/07/20 · crossref created 2020/07/20 · crossref issued 2020/08/01 · crossref published 2020/08/01 · crossref published-print 2020/08/01 · crossref deposited 2025/09/26 · openalex created_date 2025/10/10 · crossref indexed 2026/07/10 · openalex updated_date 2026/07/31

Cited by

• Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia
• Vaccines for COVID-19
• Characteristics of SARS-CoV-2 and COVID-19